TY - JOUR
T1 - Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective part 1 historical and established therapies
AU - Broadley, Simon
AU - Barnett, Michael
AU - Boggild, Mike
AU - Brew, Bruce
AU - Butzkueven, H
AU - Heard, Robert
AU - Hodgkinson, Suzanne
AU - Kermode, Allan
AU - Lechner-Scott, Jeannette
AU - Macdonell, Richard
AU - Marriott, Mark
AU - Mason, Deborah
AU - Parratt, John
AU - Reddel, Stephen
AU - Shaw, Cameron
AU - Slee, Mark
AU - Spies, Judith
AU - Taylor, Bruce
AU - Carroll, William
AU - Kilpatrick, Trevor
AU - King, John
AU - McCombe, Pamela
AU - Pollard, John
AU - Willoughby, Ernie
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.
AB - Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.
KW - Evidence-based medicine
KW - Guideline
KW - Multiple sclerosis
KW - Review
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84908373559&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2014.01.016
DO - 10.1016/j.jocn.2014.01.016
M3 - Review article
SN - 0967-5868
VL - 21
SP - 1835
EP - 1846
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
IS - 11
ER -